September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Sphingolipid Metabolism In Retinal Ischemic Preconditioning
Author Affiliations & Notes
  • Jie Fan
    Ophthalmology, Medical Univ of South Carolina, Charleston, South Carolina, United States
  • Oday Alsarraf
    Ophthalmology, Medical Univ of South Carolina, Charleston, South Carolina, United States
  • Craig E Crosson
    Ophthalmology, Medical Univ of South Carolina, Charleston, South Carolina, United States
  • Footnotes
    Commercial Relationships   Jie Fan, None; Oday Alsarraf , None; Craig Crosson, None
  • Footnotes
    Support   National Institutes of Health (NIH) Grant EY021368 (C.E.C.), NIH/NCATS grant number UL1TR000062, Unrestricted grant to the Department of Ophthalmology, Storm Eye Institute, Medical University of South Carolina, from Research to Prevent Blindness (RPB)
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4599. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jie Fan, Oday Alsarraf, Craig E Crosson; Sphingolipid Metabolism In Retinal Ischemic Preconditioning. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4599.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Previous studies have shown that retinal neuroprotective actions of ischemic preconditioning (IPC) are associated with the reduction of HDAC activity and the generation of sphingosine-1-phosphate (S1P), a bioactive molecule involved in inhibiting apoptosis. This study investigates how sphingolipid metabolism and protein acetylation interact to limit ischemic retinal injury.

Methods : Cultured astrocytes from human optic nerve head were treated with FTY720, an S1P mimetic, and HDAC activity was evaluated. Unilateral retinal ischemic was induced in rats by elevating IOP to 160 mmHg for 45 minutes. Ischemic preconditioning (5 minutes) was induced in an identical fashion at times corresponding to 24 hours prior to ischemic retinal injury. Retinal localization of acetylated histone-H3 was determined by immunohistochemistry. Sphingosine and S1P were measured by LC-MS.

Results : In astrocytes treated with FTY720 (100 μM), Class-I HDAC activity was significantly reduced by 27.8 ± 5.3%, when compared with control cultures. In rat retinas assayed 24 hours following ischemic injury, acetylated H3 staining was reduced in retinal ganglion cell layer (GCL) and inner nuclear layer (INL) when compared with control retinas. Associated with ischemic-induced reduction in acetylated histone H3 staining was an increase in Class-I HDAC activity of 21 ± 6.2%, and a reduction in S1P levels of 51.6 %. In rats subjected to IPC prior to ischemic injury, acetylated histone-H3 staining increased in the GCL and INL and was also visible in the outer nuclear layer, the increase in Class-I HDAC activity was blocked and the level of S1P was increased by 34.5%. This increase in S1P was associated with over a two fold rise in acid ceramidase activity.

Conclusions : Our results provide evidence that hypoacetylation associated with ischemic injury results from the increase in Class I HDAC activity and that neuroprotection induced by IPC is mediated in part by suppressing HDAC activity. This reduction in HDAC activity was associated with changes in sphingolipid metabolism that elevate the endogenous levels of S1P. Taken together these data support the idea that sphingolipid metabolism plays a central role in regulating HDAC activity and the retinal reponses to ischemic stress.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.